title: Humoral immune response to autologous blood transfusion in hip surgery: whole blood versus packed red cells and plasma.
abstract: OBJECTIVE
  The immune response to the transfused autologous buffy coat content in whole blood has, to date, not been studied in detail.
  
  
  METHODS
  Patients undergoing hip arthroplasty were studied according to whether they received autologous whole blood (WB) (n = 30), autologous fresh-frozen plasma and buffy coat-poor red cells (RC) (n = 40), or no transfusion (NT) (n = 27). Plasma levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and complement SC5b-9 were analysed by enzyme-linked immunosorbent assay (ELISA) 7 days after surgery.
  
  
  RESULTS
  There were no significant between-group differences regarding the time course of TNF-alpha, IL-6 and complement SC5b-9 plasma level changes, the infection rate, or the length of hospital stay.
  
  
  CONCLUSIONS
  In comparison to the impact of surgery on cytokine and complement levels, the transfusion of autologous buffy coat is not relevant.
authors.affiliation: Department of Anaesthesiology and Intensive Care Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, D-68135 Mannheim, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Tolksdorf
authors.forename: T
authors.initials: T
authors.lastname: Frietsch
authors.forename: M
authors.initials: M
authors.lastname: Quintel
authors.forename: M
authors.initials: M
authors.lastname: Kirschfink
authors.forename: P
authors.initials: P
authors.lastname: Becker
authors.forename: A
authors.initials: A
authors.lastname: Lorentz
mesh_terms: D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects*; D019644:Arthroplasty, Replacement, Hip / Q000379:methods*; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods; D001793:Blood Preservation / Q000379:methods; D001804:Blood Transfusion, Autologous / Q000009:adverse effects* / Q000379:methods; D015331:Cohort Studies; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000032:analysis / Q000276:immunology / Q000494:pharmacology; D015925:Cryopreservation / Q000379:methods; D005260:Female; D006023:Glycoproteins / Q000032:analysis / Q000276:immunology / Q000494:pharmacology; D006801:Humans; D007239:Infections / Q000209:etiology; D018836:Inflammation Mediators / Q000032:analysis / Q000276:immunology / Q000494:pharmacology; D015850:Interleukin-6 / Q000032:analysis / Q000276:immunology / Q000494:pharmacology; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000276:immunology / Q000494:pharmacology
chemical_list: D015938:Complement Membrane Attack Complex; D006023:Glycoproteins; D018836:Inflammation Mediators; D015850:Interleukin-6; C047610:SC5b-9 protein complex; D014409:Tumor Necrosis Factor-alpha; D003165:Complement System Proteins